Vipergen establishes research partnership with aligos therapeutics focused on dna encoded library (del)-based drug discovery for viral infections and liver diseases

Copenhagen, denmark, nov. 23, 2021 /prnewswire/ -- vipergen, a leading provider of small-molecule drug discovery services based on dna-encoded library (del) technologies, announced today the signing of a multi-target drug discovery agreement with aligos therapeutics, inc. (nasdaq: algs). under the terms of the agreement, vipergen will apply its high-fidelity del technology platforms to identify novel small-molecule compounds that bind to selected aligos protein targets.
ALGS Ratings Summary
Quant
ALGS Quant Ranking
Sector
Industry
Quant Rating
Quant Score